TY - JOUR
T1 - The effects of antibiotics on the blood coagulation system after urological surgery
AU - Tsugawa, Masaya
AU - Yamada, Daisuke
AU - Nasu, Yoshitsugu
AU - Kishi, Mikio
AU - Mizuno, Akihiro
AU - Kumon, Hiromi
AU - Ohmori, Hiroyuki
PY - 1989/1/1
Y1 - 1989/1/1
N2 - We investigated the effects of various antibiotics on the blood coagulation system in patients who had received surgical treatment for urological disease. Latamoxef (LMOX)(group A, 91 cases), cefbuperazone (CBPZ)(group B, 48 cases), cefamandole (CMD)(group C, 29 cases) or cefoxitin (CFX)(group D, 33 cases) was administered intravenously at a dose of 4g/day for 7 consecutive days after surgery. Each group was subdivided into a vitamin K2 (K2) treatment group and a nontreatment group; the patients in the K2 group received K2 in travenously at a dose of 100mg/day for 7 consecutive days after surgery. The blood coagulation parameters determined were: prothrombin time (PT), hepaplastin test (HPT), activated partial thromboplastin time (APTT), thrombotest (TT), fibrinogen, and thrombocyte count. All these parameters were measured before and 2, 4, and 8 days after surgery. In all groups (A, B, C, D), a slight change occurred in PT, HPT, APTT, TT, fibrinogen, and thrombocyte count 2 or 4 days after surgery. At this time, there was no difference between the K2 treatment and nontreatment groups. These changes were attributed mainly to the effects of surgery rather than to the antibiotics themselves. The effect of aging, a potential risk factor of the blood coagulation system, was also investigated in group A; there was no difference between the elderly patient group (≥70 years) and the counterpart group (<70 years). All patients were further divided into 2 groups: the nonlaparotomy group (ingestion possible even on the day of surgery), and the laparotomy group (ingestion not possible on the day of surgery). No difference was observed between the K2 treatment and nontreatment groups.
AB - We investigated the effects of various antibiotics on the blood coagulation system in patients who had received surgical treatment for urological disease. Latamoxef (LMOX)(group A, 91 cases), cefbuperazone (CBPZ)(group B, 48 cases), cefamandole (CMD)(group C, 29 cases) or cefoxitin (CFX)(group D, 33 cases) was administered intravenously at a dose of 4g/day for 7 consecutive days after surgery. Each group was subdivided into a vitamin K2 (K2) treatment group and a nontreatment group; the patients in the K2 group received K2 in travenously at a dose of 100mg/day for 7 consecutive days after surgery. The blood coagulation parameters determined were: prothrombin time (PT), hepaplastin test (HPT), activated partial thromboplastin time (APTT), thrombotest (TT), fibrinogen, and thrombocyte count. All these parameters were measured before and 2, 4, and 8 days after surgery. In all groups (A, B, C, D), a slight change occurred in PT, HPT, APTT, TT, fibrinogen, and thrombocyte count 2 or 4 days after surgery. At this time, there was no difference between the K2 treatment and nontreatment groups. These changes were attributed mainly to the effects of surgery rather than to the antibiotics themselves. The effect of aging, a potential risk factor of the blood coagulation system, was also investigated in group A; there was no difference between the elderly patient group (≥70 years) and the counterpart group (<70 years). All patients were further divided into 2 groups: the nonlaparotomy group (ingestion possible even on the day of surgery), and the laparotomy group (ingestion not possible on the day of surgery). No difference was observed between the K2 treatment and nontreatment groups.
UR - http://www.scopus.com/inward/record.url?scp=0024451368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024451368&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.37.1050
DO - 10.11250/chemotherapy1953.37.1050
M3 - Article
AN - SCOPUS:0024451368
VL - 37
SP - 1050
EP - 1061
JO - Chemotherapy
JF - Chemotherapy
SN - 0009-3165
IS - 8
ER -